-
1 . Academic Journal
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- 저자
- by Tomczak, Piotr; Choueiri, Toni; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas R., et al.
- 소스
- In The Lancet Oncology September 2022 23(9):1133-1144
-